- Imugene has received guidance from the U.S. Food and Drug Administration (FDA) for the development of VAXinia
- The FDA provided guidance on a development plan for a phase one study design as well as feedback on part two of the study
- VAXinia is an oncolytic virotherapy drug that is being developed to treat various cancers
- Given the uncertainty during the COVID-19 pandemic, Imugene considers it important to be flexible with identifying regulatory pathways
- Imugene is also seeking a regulatory pathway in Australia
- Company shares are up 2.68 per cent and are trading for 5.8 cents
